Mimicking gene defects to treat drug dependence

Annals of the New York Academy of Sciences

Volumn 909, Issue , 2000, Pages 233-246

  Sellers, Edward M ^a,b,c,d,e   Tyndale, Rachel F ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

222; AMPHETAMINE; ANALGESIC AGENT; CARCINOGEN; CODEINE; COTININE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; DRUG RECEPTOR; FLUNITRAZEPAM; METHAMPHETAMINE; METHOXSALEN; MORPHINE; NICOTINE; OPIATE; PARACETAMOL; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

CIGARETTE SMOKING; CONFERENCE PAPER; DRUG ABUSE; DRUG ACTIVATION; DRUG DEPENDENCE; DRUG METABOLISM; ENZYME INACTIVATION; GENE MUTATION; GENE THERAPY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PHENOTYPE; RISK FACTOR; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

EID: 0033940293     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06685.x     Document Type: Conference Paper

References (60)

1. 1. TRUE, W.R., A.C. HEATH, J.F. SCHERRER, B. WATERMAN, J. GOLDBERG, N. LIN, S.A. EISEN, M.J. LYONS & M.T. TSUANG. 1997. Genetic and environmental contributions to smoking. Addiction 92(10): 1277-1287.
2. 2. NELSON, D.R., T. KAMATAKI, D.J. WAXMAN, F.P. GUENGERICH & R.W. ESTABROOK. 1993. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell. Biol. 12(1): 1-51.
3. 3. MAHGOUB, A., J.R. IDLE, L.G. DRING, R. LANCASTER & R.L. SMITH. 1977. Polymorphic hydroxylation of debrosoquine in man. Lancet 2: 584-586.
4. 4. EICHELBAUM, M., S. MINESHITA, E.E. OHNHAUS & C. ZEKORN. 1986. The influence of enzyme induction on polymorphic sparteine oxidation. Br. J. Clin. Pharmacol. 22: 49-53.
5. 5. VINCENT-VIRY, M., J. MULLER, B. FOURNIER, M.M. GALTEAU & G. SLEST. 1991. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Clin. Chem. 37(3): 327-332.
6. 6. KALOW, W. 1991. Interethnic variation of drug metabolism. Trends Pharmaceut. Sci. 12: 102-107.
7. 7. HANIOKA, N., S. KIMURA, U. MEYER & F.J. GONZALEZ. 1990. The human CYP2D6 locus associated with a common genetic defect in drug oxidation: a G1934 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Human Gen. 47: 994-1001.
8. 8. KAGIMOTO, M., M. HEIM, K. KAGIMOTO, T. ZEUGIN & U.A. MEYER. 1990. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265: 17209-17214.
9. 9. GAEDIGK, A., M. BLUM, R. GAEDIGK, M. EICHELBAUM & U.A. MEYER. 1991. Deletion of the entire cytochrome P-450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Human Gen. 48: 943-950.
10. 10. TYNDALE, R.F., T. AOYAMA, F. BROLY, T. MATSUNAGA, T. INABA, W. KALOW, H.V. GELBOIN, U.A. MEYER, & F.J. GONZALEZ. 1991. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1: 26-32.
11. 11. BROLY, F. & U.A. MEYER. 1993. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 3(3): 123-130.
12. 12. JOHANSSON, I., E. LUNDQVIST, L. BERTILSSON, M.L. DAHL, F. SJOQVIST & M. INGELMAN-SUNDBERG. 1993. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90(24): 11825-11829.
13. 13. JOHANSSON, I., M. OSCARSON, Q.Y. YUE, L. BERTILSSON, F. SJOQVIST & M. INGELMAN-SUNDBERG. 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46(3): 452-459.
14. 14. MEYER, U.A. 1994. The molecular basis of genetic polymorphisms of drug metabolism. J. Pharm. Pharmacol. 46(Suppl. 1): 409-415.
15. 15. KITCHEN, I., J. TREMBLAY, J. ANDRE, L.G. DRING, J.R. IDLE, R.L. SMITH & R.T. WILLIAMS. 1979. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9: 397-404.
16. 16. SCHMID, B., J. BIRCHER, R. PREISIG & A. KUPFER. 1985. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin. Pharmacol. Ther. 38: 618-624.
17. 17. CHEN, Z.R., A.A. SOMOGYI & F. BOCHNER. 1988. Polymorphic O-demethylation of codeine. Lancet 2: 914-915.
18. 18. OTTON, S.V., M. SCHADEL, S.W. CHEUNG, H.L. KAPLAN, U.E. BUSTO & E.M. SELLERS. 1993. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54(5): 463-472.
19. 19. ISBELL, H. & H.F. FRASER. 1953. Actions and addiction liabilities of Dromoran derivatives in man. J. Pharmacol. Exp. Ther. 107: 524-530.
20. 20. McELWEE, N.E. & J.C. VELTRI. 1990. International abuse of dextromethorphan (DM) products: 1985 to 1988 statewide data. Vet. Human Toxicol. 32: 355.
21. 21. HOLTZMAN, S.G. 1980. Phencyclidine-like discriminative effects of opioids in the rat. J. Pharmacol. Exp. Ther. 214: 614-619.
22. 22. MUSACCHIO, J.M., M. KLEIN & L.J. SANTIAGO. 1988. High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions. J. Pharmacol. Exp. Ther. 247: 424-431.
23. 23. TORTELLA, F.C., M. PELLICANO & N.G. BOWERY. 1989. Dextromethorphan and neuromodulation: Old drug coughs up new activities. Trends Pharmacol. Sci. 10: 501-507.
24. 24. SCHADEL, M., D. WU, S.V. OTTON, W. KALOW & E.M. SELLERS. 1995. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol. 15(5): 263-269.
25. 25. ZAWERTAILO, L.A., H.L. KAPLAN, U.E. BUSTO, R.F. TYNDALE & E.M. SELLERS. 1996. The cytochrome P450 2D6 (CYP2D6) polymorphism affects abuse properties of dextromethorphan (DEX). Abstracts of College on Problems of Drug Dependence, Fifty-Eighth Annual Scientific Meeting (San Juan, Puerto Rico) :156.
26. 26. ZAWERTAILO, L.A., U.E. BUSTO, R.F. TYNDALE & E.M. SELLERS. 1998. Dextromethorphan's active metabolite contributes to its abuse liability [abstract]. Clin. Pharmacol. Ther. 63(2): 217.
27. 27. BUSTO, U.E., B.A. SPROULE, K. KNIGHT, M.K. ROMACH & E.M. SELLERS. 1998. Severe dependence on oral opioids. Can. J. Clin. Pharmacol. 15(1): 23-28.
28. 28. ROMACH, M.K., B.A. SPROULE, E.M. SELLERS, G. SOMER & U.E. BUSTO. 1999a. Long-term codeine use is associated with depressive symptoms. J. Clin. Psychopharmacol. 19(4): 373-376.
29. 29. DROLL, K.P., E.M. SELLERS & R.F. TYNDALE. 1996. The cytochrome P450 2D6 gene: a genetic risk factor in oral opiate dependence. Abstracts of XIth International Symposium on Microsomes and Drug Oxidations (Los Angeles, CA): 211.
30. 30. KATHIRAMALAINATHAN, K., H.L. KAPLAN, U.E. BUSTO, M.K. ROMACH, R.F. TYNDALE & E.M. SELLERS. 1996. Inhibition of cytochrome P450 2D6 modifies codeine metabolism and abuse liability. Abstracts of XIth International Symposium on Microsomes and Drug Oxidations (Los Angeles, CA): 239.
31. 31. ROMACH, M.K., S.V. OTTON, G. SOMER, R.F. TYNDALE & E.M. SELLERS. 2000. Cytochrome P450 2D6 and treatment of codeine dependence. J. Clin. Psychopharmacol. 20(1): 43-45.
32. 32. ROMACH, M.K., E.M. SELLERS, B.A. SPROULE, D. GRACIAS & R.F. TYNDALE. 1995. Developing strategies to treat prescription opiate dependence and comorbid disorders. American College of Neuropsychopharmacology 34th Annual Meeting, Scientific Abstracts (San Juan, Puerto Rico): 190.
33. 33. KAPLAN, H.L., J.A. OCAMPO-MORA, U.E. BUSTO, R.F. TYNDALE & E.M. SELLERS. 1996. Differential sensitivity to methamphetamine serum concentration in extensive and poor CYP2D6 metabolizers. Abstracts College on Problems of Drug Dependence, Fifty-Eighth Annual Scientific Meeting (San Juan, Puerto Rico): 69.
34. 34. KILICARSLAN, T., U. BUSTO, R.F. TYNDALE & E.M. SELLERS. 1998. Flunitrazepam: Polymorphic metabolism by CYP2C19 [abstract]. Clin. Pharmacol. Ther. 63(2): 218.
35. 35. BENOWITZ, N.L., P. JACOB 3RD, I. FONG & S. GUPTA. 1994. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268(1): 296-303.
36. 36. NAKAJIMA, M., T. YAMAMOTO, K. NUNOYA, T. YOKOI, K. NAGASHIMA, K. INOUE, Y. FUNAE, N. SHIMADA, T. KAMATAKI & Y. KUROIWA. 1996. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 11: 1212-1217.
37. 37. MESSINA, E.S., R.F. TYNDALE & E.M. SELLERS. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282(3): 1608-1614.
38. 38. YAMANO, S., J. TATSUNO & F.J. GONZALEZ. 1990. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29(5): 1322-1329.
39. 39. CHOLERTON, S., M.E. IDLE, A. VAS, F.J. GONZALEZ & J.R. IDLE. 1992. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J. Chromatogr. 575(2): 325-330.
40. 40. RAUTIO, A., H. KRAUL, A. KOJO, E. SALMELA & O. PELKONEN. 1992. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2(5): 227-233.
41. 41. ISCAN, M., H. ROSTAMI, M. ISCAN, T. GURAY, O. PELKONEN & A. RAUTIO. 1994. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur. J. Clin. Pharmacol. 47(4): 315-318.
42. 42. FERNANDEZ-SALGUERO, P., S.M.G. HOFFMAN, S. CHOLERTON, H. MOHRENWEISER, H. RAUNIO, A. RAUTIO, O. PELKONEN, J. HUANG, W.E. EVANS, J.R. IDLE & F.J. GONZALEZ. 1995. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Human Gen. 57: 651-660.
43. 43. RAUTIO, A., H. GULLSTEN, O. PELKONEN & H. RAUNIO. 1996. CYP2A6 polymorphism. Abstracts of XIth International Symposium on Microsomes and Drug Oxidations (Los Angeles, CA): 146.
44. 44. PIANEZZA, M., E.M. SELLERS & R.F. TYNDALE. 1998. A common genetic defect in nicotine metabolism decreases smoking. Nature 393(6687): 750.
45. 45. McMORROW, M.J. & R.M. FOXX. 1983. Nicotine's role in smoking: an analysis of nicotine regulation. Psychol. Bull. 93(2): 302-327.
46. 46. RUSSEL, M. S. H. 1987. Nicotine intake and its regulation by smokers. In Advances in Behavioral Biology. W.R. Martin, G.R. Vauhon, E.T. Iwamoto & L. David, Eds.: 25-50. Plenum Press. New York.
47. 47. OSCARSON, M., R.A. MCLELLAN, H. GULLSTEN, Q.Y. YUE, M.A. LANG, M.L. BERNAL, B. SINUES, A. HIRVONEN, H. RAUNIO, O. PELKONEN & M. INGELMAN-SUNDBERG. 1999. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448(1): 105-110.
48. 48. NUNOYA, K., T. YOKOI, Y. TAKAHASHI, K. KIMURA, M. KINOSHITA & T. KAMATAKI. 1999. Homologous unequal crossover within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J. Biochem. 126: 402-407.
49. 49. TYNDALE, R.F., Y. RAO, L. BODIN, M. ZIA, M. ZEMAN, E. HOFFMANN & E.M. SELLERS. 2000. CYP2A6 gene defects and duplications alter objective indices of smoking [abstract]. Clin. Pharmacol. Ther. 67(2): 113.
50. 50. CRESPI, C.L., B.W. PENMAN, J.A. LEAKEY, M.P. ARLOTTO, A. STARK, A. PARKINSON, T. TURNER, D.T. STEIMEL, K. RUDO, R.L. DAVIES, et al. 1990. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11(8): 1293-1300.
51. 51. YAMAZAKI, H., Y. INUI, C.H. YUN, F.P. GUENGERICH & T. SHIMADA. 1992. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13(10): 1789-1794.
52. 52. NOWAK, M., E.M. SELLERS & R.F. TYNDALE. 1998. Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin. Pharmacol. Ther. 64(4): 378-383.
53. 53. YOKOI, T. & T. KAMATAKI. 1998. Genetic polymorphism of drug metabolizing enzymes: New mutations in the CYP2D6 and CYP2A6 genes in Japanese. Pharm. Res. 4: 517-524.
54. 54. GROEGER, A.M., M.R. MUELLER, O. ODOCHA, G. DEKAN, A. SALAT, W. ROTHY, V. ESPOSITO, M. CAPUTI, E. WOLNER & H.E. KAISER. 1997. Ethnic variations in lung cancer. Anticancer Res. 17(4A): 2849-2857.
55. 55. LAW, M.R., J.K. MORRIS, H.C. WATT & N.J. WALD. 1997. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. Br. J. Cancer 75: 1690-1693.
56. 56. MIYAMOTO, M., Y. UMETSU, H. DOSAKA-AKITA, Y. SAWAMURA, J. YOKOTA, H. KUNITOH, N. NEMOTO, K. SATO, N. ARIYOSHI & T. KAMATAKI. 1999. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261(3): 658-660.
57. 57. SELLERS, E.M., M. ZEMAN, H.L. KAPLAN & R.F. TYNDALE. 2000. Inhibition of cytochrome P450 2A6 (CYP2A6) decreases smoking and activation of the procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [abstract]. Clin. Pharmacol. Ther. 67(2): 113
58. 58. ZHANG, W., T. KILICARSLAN, R.F. TYNDALE & E.M. SELLERS. 2000. Identification of selective and specific inhibitors of CYP2A6 [abstract]. Clin. Pharmacol. Ther. 67(2): 116.
59. 59. TYNDALE, R.F., Y. LI, H.L. KAPLAN & E.M. SELLERS. 1999. Inhibition of nicotine's metabolism: a potential new treatment for tobacco dependence [abstract]. Clin. Pharmacol. Ther. 65(2): 145.
60. 60. SELLERS, E.M., H.L. KAPLAN, M.K. ROMACH & R.F. TYNDALE. 1999. Inhibition of CYP2A6 decreases smoking. Clin. Pharmacol. Ther. 65(2): 153.